Seqirus--the world's second largest flu vaccine player formed from CSL's purchase of Novartis' ($NVS) flu vaccines--is expanding in the U.K. It'll spend £15.3 million ($21.3 million) on a new flu vaccine manufacturing site in Speke, an announcement the company made as it opened a £6.8 million warehouse there. The company is the second largest flu vaccine player, behind Sanofi ($SNY), with more than 2,000 employees worldwide. More from FiercePharmaManufacturing